Progyny, Inc. (NASDAQ:PGNY) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on Progyny, with nine buy ratings, three holds and one strong buy. The average 12-month price target is $33.91, above the reported $26.37 opening price.
• Progyny’s latest quarterly results exceeded expectations, with adjusted EPS of $0.55 versus the $0.33 consensus and revenue of $350.5 million. Revenue increased 5.3% year over year, and the company issued third-quarter and full-year 2026 earnings guidance.
• The board authorized a $200 million share-repurchase program, allowing the company to buy back up to 10.3% of outstanding shares. Institutional investors own 94.93% of Progyny, while insiders sold $351,968 worth of shares during the last quarter.

Shares of Progyny, Inc. (NASDAQ:PGNY - Get Free Report) have been given an average rating of "Moderate Buy" by the thirteen analysts that are covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $33.9091.

Several equities analysts recently commented on the stock. Barclays decreased their price objective on shares of Progyny from $34.00 to $30.00 and set an "equal weight" rating for the company in a research report on Wednesday, August 12th. Leerink Partners set a $38.00 target price on shares of Progyny in a research report on Wednesday, July 22nd. Wall Street Zen lowered shares of Progyny from a "strong-buy" rating to a "buy" rating in a research note on Saturday, July 25th. KeyCorp raised their price target on shares of Progyny from $30.00 to $35.00 and gave the stock an "overweight" rating in a report on Monday, July 13th. Finally, Canaccord Genuity Group set a $35.00 price target on shares of Progyny in a report on Friday, August 7th.

Progyny Trading Up 2.1%

NASDAQ PGNY opened at $26.37 on Thursday. The firm's fifty day simple moving average is $29.08 and its two-hundred day simple moving average is $23.58. Progyny has a 12-month low of $16.10 and a 12-month high of $33.06. The firm has a market capitalization of $2.02 billion, a P/E ratio of 28.66, a P/E/G ratio of 1.87 and a beta of 1.01.

Progyny (NASDAQ:PGNY - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.55 EPS for the quarter, beating the consensus estimate of $0.33 by $0.22. Progyny had a return on equity of 15.98% and a net margin of 6.00%.The firm had revenue of $350.51 million during the quarter, compared to analyst estimates of $349.05 million. During the same quarter in the prior year, the business posted $0.19 EPS. The business's revenue for the quarter was up 5.3% compared to the same quarter last year. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. As a group, sell-side analysts predict that Progyny will post 1.19 earnings per share for the current fiscal year.

Progyny announced that its Board of Directors has authorized a share repurchase plan on Tuesday, May 26th that authorizes the company to buyback $200.00 million in outstanding shares. This buyback authorization authorizes the company to purchase up to 10.3% of its shares through open market purchases. Shares buyback plans are usually a sign that the company's board of directors believes its shares are undervalued.

Insider Transactions at Progyny

In related news, CFO Mark S. Livingston sold 2,517 shares of the firm's stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $25.50, for a total value of $64,183.50. Following the completion of the transaction, the chief financial officer owned 74,688 shares in the company, valued at $1,904,544. This trade represents a 3.26% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Allison Swartz sold 1,199 shares of Progyny stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $25.02, for a total value of $29,998.98. Following the sale, the executive vice president directly owned 83,316 shares of the company's stock, valued at approximately $2,084,566.32. This represents a 1.42% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,563 shares of company stock valued at $351,968 in the last quarter. Insiders own 9.90% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of PGNY. Caitong International Asset Management Co. Ltd purchased a new stake in Progyny in the fourth quarter valued at approximately $25,000. Public Employees Retirement System of Ohio purchased a new position in Progyny during the 2nd quarter worth approximately $29,000. Nykredit A S acquired a new stake in Progyny during the 2nd quarter valued at approximately $38,000. Hantz Financial Services Inc. lifted its stake in Progyny by 79.4% during the 4th quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company's stock valued at $43,000 after acquiring an additional 742 shares during the period. Finally, Toth Financial Advisory Corp purchased a new stake in shares of Progyny in the 2nd quarter valued at $65,000. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company's digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny's offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source